Novartis International AG

Warning! As of 20 September 2021, the EU lobby register has changed format. Temporarily, the register is no longer providing daily data updates of all lobby data which means that the figures on LobbyFacts cannot currently be kept up-to-date. If, for example, you see a company, trade association, or lobby consultancy with "no figure available" for EU lobby costs, open the data card, and click the link to the EU lobby register where you will find the updated registration including EU lobby costs declaration. Regretably, under the lobby register format, NGOs and think tanks are no longer required to provide a figure for EU lobby costs. We will update LobbyFacts with the new data as soon as possible.

Tweet this page
How to read and use this data card.

Lobbying costs:

WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.

WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.

2,250,000€ - 2,499,999€

Financial year: 01/01/2020 - 01/12/2020

Lobbyists declared: 3.5 FTE (8)

WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.


Lobbyists with EP accreditation: 4


Meetings with European Commission: 23

Lobbying costs over the years:


Novartis International AG

Registration on EU Transparency Register

91269481588-28 (First registered: 27 Apr 2009)

Goals / Remit

Our mission is to discover new ways to improve and extend people's lives.
We use science-based innovation to address some of society's most challenging healthcare issues.
We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
We also aim to provide a shareholder return that rewards those who invest their money, time and ideas in our company.


Antimicrobial resistance (AMR), ATMP Regulation, Big data, Biosimilars & generics, Clinical Trials Regulation, Data Protection Regulation, EU IP policy, EU Relative Efficacy Assessment (EU REA), EU research policy, EU trade policy, Health Systems Performance Assessment, Health Technology Assessment & Market Access, Industrial policy, Innovative Medicines Initiative (IMI), Outcomes-based healthcare systems, Orphan Medicinal Products Regulation, Paediatric Regulation, Patient access to innovation, Patient safety, Pharmaceuticals in the environment, Sustainable Development Goals


Head office:
Novartis International AG Forum 1 Forum 1
Basel CH-4002

Tel: 41 61 324 11 11

Belgium office:
Rue Belliard 40
Brussels ,

Tel: 32 2 246 1975